单次尿激酶静脉溶栓治疗超早期脑梗死临床研究

The clinical study of single intravenous thrombolysis with Urokinase in patients with ultra-acute cerebral infarction

目的探讨尿激酶早期静脉溶栓治疗超早期脑梗死的临床疗效。方法将超早期脑梗死患者分为溶栓组与对照组。溶栓组126例3h内的急性脑梗死患者应用70万单位尿激酶单次静脉滴注溶栓治疗,对照组140例给予口服阿司匹林75mg/d,其余治疗两组相同。观察溶栓后2h、24h、7d、14dNIHSS评分下降程度及治疗后的基本治愈率、总有效率,并与常规治疗的对照组比较。结果溶栓后24hNIHSS较溶栓前明显降低,两者比较差异有统计学意义(P<0.01);溶栓后14dNIHSS下降程度、基本治愈率、总有效率明显高于对照组(P<0.01)。结论单次尿激酶静脉溶栓治疗超早期脑梗死是相对安全而且有效的方法。

Objective To investigate the clinical efficiency of intravenous thrombolysis with Urokinase in patients with ultra-acute cerebral infarction.Methods The patients with ultra-acute cerebral infarction were divided into a thrombolytic group or a control group.In thrombolytic group,UK 0.7 MU was injected by drip within 3 hours;the patients in control group were treated with Aspirin orally 75mg once a day.Except for the injection of Urokinase,the same procedure was done in the two groups.The neurological functional deficit scale,basic cure and the total effective rate were compared with at intervals of 2 hours,4 hours,7days,14days.Results In thrombolytic group,the National Institutes of Health Stroke Scale（NIHSS） reduced Significantly（P〈0.01） at 24 hours;The neurological functional deficit scale,basic cure and the total effective rate in thrombolytic group were increased significantly higher than those in the control group after 14 days（P〈0.01）.Conclusion Urokinase is effective and safe for the patients with ultra-acute cerebral infarction.